Clinical Trial Search

Primary: Progression-Free Survival (PFS) — 69; 61 Number of events

Primary: Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) — 162414.81; 167309.07; 172450.97 h*μg/mL

Primary: Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 — -13.6; -17.8 score on a scale — p=0.0028

Primary: Overall Response Rate (Main Cohort) — 77.1 percentage of participants — p=<0.001

Primary: Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1) — 0; 3 Participants

Primary: Number of Patients With Adverse Drug Reactions (ADRs) — 30 Participants

Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants

Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear From Baseline at Week 12 — 50.1; 25.9 Percentage of Participants

Primary: Overall Survival (OS) — 17.2; 15.3 Months — p=0.2262

Primary: Hemoglobin A1C (HbA1C) — 8.4; 8.3 Percentage of glycated hemoglobin

Primary: Overground Self-Selected Walking Speed Using Hip Exoskeleton Assistance — 87.03; 87.96; 90.4; 93.05 centimeters per second — p=0.000005

Primary: Progression Free Survival (PFS) — 9.53; 8.28 months — p=0.027

Primary: Adverse Events in Study Groups Following Exposure to Pb(PfCS@UIS4)-Infected Mosquitoes [Safety] — 0; 3; 10; 9 numbers of adverse events

Primary: The GRID-Hamilton Depression Rating Scale (GRID-HAMD) — 22.9; 22.5; NA; 23.8 units on a scale

Primary: PFS